{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:46:48Z","timestamp":1791802008724,"version":"4.3.4"},"reference-count":53,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Inherited CD59 deficiency is a rare autosomal recessive complement-mediated disorder caused by biallelic loss-of-function variants in the CD59 gene. It typically presents in infancy with Coombs-negative hemolytic anemia, relapsing demyelinating polyneuropathy, and recurrent ischemic strokes. Diagnosis is often delayed due to overlapping with more common neurological and hematological disorders. The present study was carried out to systematically review the literature on congenital CD59 deficiency, focusing on genotype\u2013phenotype correlations, geographic distribution, clinical presentation, diagnostic approaches, and treatment outcomes. Methods: Eligible studies included case reports and case series of genetically or functionally confirmed inherited CD59 deficiency. Demographic, molecular, clinical, and therapeutic data were extracted and analyzed descriptively. Results: 20 reports included. Evidence remains mainly limited to case reports and small case series. The disorder demonstrates a severe and heterogeneous phenotype with predominant neuromuscular involvement, frequently associated with hematologic and cerebrovascular manifestations. Most reported cases originate from regions with high consanguinity, particularly the Middle East and Asia, suggesting possible founder effects and underrecognized prevalence. Exploratory analysis suggested a possible relationship between predicted variant functional impact and clinical severity. However, given the small and heterogeneous evidence base, this finding should be considered hypothesis-generating. Responses to conventional immunomodulatory therapies are variable and often transient. Eculizumab has shown clinical benefit in some patients, although treatment responses remain inconsistent. Conclusions: Congenital CD59 deficiency is a severe and underrecognized complement-mediated disorder with major diagnostic and therapeutic challenges. Current evidence remains insufficient to establish definitive genotype\u2013phenotype correlations or standardized management strategies. Increased clinical awareness, early integration of functional and genetic testing, and further studies are needed to improve diagnosis and optimize treatment outcomes.<\/jats:p>","DOI":"10.3390\/jcm15197751","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:40:17Z","timestamp":1791596417000},"page":"7751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Congenital\/Inherited CD59 Deficiency: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7651-0590","authenticated-orcid":false,"given":"Lama","family":"Alwahiby","sequence":"first","affiliation":[{"name":"College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5138-847X","authenticated-orcid":false,"given":"Lanah","family":"Alsuhim","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4483-1428","authenticated-orcid":false,"given":"Manal","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalnar","family":"Albaloshi","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-1973","authenticated-orcid":false,"given":"Cristina","family":"Skrypnyk","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, AlJawhara Center, College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/hematolrep14020025","article-title":"A Splice Site Mutation Associated with Congenital CD59 Deficiency","volume":"14","author":"Chai","year":"2022","journal-title":"Hematol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1212\/NXG.0000000000000280","article-title":"Molecular pathogenesis of human CD59 deficiency","volume":"4","author":"Karbian","year":"2018","journal-title":"Neurol. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molimm.2015.03.005","article-title":"Paroxysmal nocturnal hemoglobinuria (PNH) and primary p.Cys89Tyr mutation in CD59: Differences and similarities","volume":"67","author":"Mevorach","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4103\/aian.aian_1084_24","article-title":"Congenital CD59 Deficiency-A Novel Cause of Relapsing-Remitting Polyneuropathy","volume":"28","author":"Cornelius","year":"2025","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.17712\/nsj.2023.2.20220119","article-title":"Inherited CD59 deficiency, where neurology and genetics intertwine","volume":"28","author":"Almutawea","year":"2023","journal-title":"Neurosciences"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MPH.0000000000003008","article-title":"Tracing a Rare Genetic Disease: Familial Congenital CD59 Deficiency and Carrier Cases Identified Through Village Screening","volume":"47","author":"Medine","year":"2025","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation","volume":"80","author":"Mevorach","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_8","first-page":"184","article-title":"CD59 Deficiency in Two Bahraini Children: Clinical Profile and Outcome","volume":"5","author":"Ali","year":"2021","journal-title":"J. Pediatr. Neurol. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","article-title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy","volume":"121","author":"Nevo","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0037-1604483","article-title":"Neonatal-Onset Recurrent Guillain-Barr\u00e9 Syndrome-Like Disease: Clues for Inherited CD59 Deficiency","volume":"48","author":"Ardicli","year":"2017","journal-title":"Neuropediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejpn.2015.07.001","article-title":"Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency","volume":"19","author":"Tabib","year":"2015","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.24953\/turkjped.2021.1405","article-title":"Optic neuritis in CD59 deficiency: An extremely rare presentation","volume":"64","author":"Uzan","year":"2022","journal-title":"Turk. J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ejpn.2018.04.003","article-title":"CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels","volume":"22","author":"Klemann","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_14","first-page":"201","article-title":"Development of Type 1 Diabetes in a Child with Inherited CD59 Deficiency Treated with Eculizumab","volume":"86","author":"Koca","year":"2016","journal-title":"Horm. Res. Paediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1308104","article-title":"Targeted therapy with eculizumab for inherited CD59 deficiency","volume":"370","author":"Kyrieleis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/ejh.13970","article-title":"Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting","volume":"111","author":"Versmold","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_17","unstructured":"(2026, July 01). Hemolytic Anemia, CD59-Mediated, with or without Immune-Mediated Polyneuropathy; HACD59. CD59 Deficiency. Available online: https:\/\/www.omim.org\/entry\/612300."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-017-0622-4","article-title":"Australian children living with rare diseases: Experiences of diagnosis and perceived consequences of diagnostic delays","volume":"12","author":"Zurynski","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/joor.12633","article-title":"Association between psychotropic medications and presence of sleep bruxism: A systematic review","volume":"45","author":"Melo","year":"2018","journal-title":"J. Oral Rehabil."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/eji.1830221029","article-title":"Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene","volume":"22","author":"Motoyama","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/CPJ.0000000000000511","article-title":"Uncontrolled inflammation of the nervous system: Inherited CD59 deficiency","volume":"8","author":"Yuksel","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"ref_23","first-page":"e84085","article-title":"Complement Dysregulation in Infancy: A Case of CD59 Deficiency with Neurological Sequelae","volume":"17","author":"Busaleh","year":"2025","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0041-1742160","article-title":"Recurrent Blistering Skin Lesions and Reversible Monocular Abducens Paralysis in a Patient with CD59 Deficiency","volume":"53","author":"Demirsoy","year":"2022","journal-title":"Neuropediatrics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0039-3399583","article-title":"Recurrent demyelinating episodes as sole manifestation of inherited CD59 deficiency","volume":"51","author":"Solmaz","year":"2020","journal-title":"Neuropediatrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13317-020-00132-2","article-title":"Recurrent angioedema, Guillain-Barr\u00e9, and myelitis in a girl with systemic lupus erythematosus and CD59 deficiency syndrome","volume":"11","author":"Ghasemi","year":"2020","journal-title":"Autoimmun. Highlights"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.0000000000001391","article-title":"Early-onset chronic axonal neuropathy, strokes, and hemolysis: Inherited CD59 deficiency","volume":"84","author":"Haliloglu","year":"2015","journal-title":"Neurology"},{"key":"ref_28","first-page":"1411","article-title":"New Name? CD59-Related Immune-Mediated Polyneuropathy with\/without Hemolytic Anemia?","volume":"27","author":"Gumus","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2015.01.006","article-title":"Congenital CD59 Deficiency","volume":"29","author":"Schrezenmeier","year":"2015","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/1380-2933(95)00018-6","article-title":"CD59: Its role in complement regulation and potential for therapeutic use","volume":"1","author":"Sugita","year":"1995","journal-title":"Immunotechnology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Duchateau, L., Mart\u00edn-Aguilar, L., Lleix\u00e0, C., Cortese, A., Dols-Icardo, O., Cervera-Carles, L., Pascual-Go\u00f1i, E., Diaz-Manera, J., Calegari, I., and Franciotta, D. (2019). Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 14, Erratum in PLoS ONE\u00a02019, 14, e0215784. https:\/\/doi.org\/10.1371\/journal.pone.0215784.","DOI":"10.1371\/journal.pone.0215784"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e16365","DOI":"10.1111\/ene.16365","article-title":"Guillain-Barr\u00e9 syndrome: A comprehensive review","volume":"31","author":"Bellanti","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100196","DOI":"10.1016\/j.nerep.2023.100196","article-title":"Chronic inflammatory demyelinating polyneuropathy or subacute Guillain-Barr\u00e9 syndrome? Not always an easy differential diagnosis","volume":"5","author":"Cecconi","year":"2024","journal-title":"Neuroimmunol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014Understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1002\/cphg.98","article-title":"Clinical Interpretation of Sequence Variants","volume":"106","author":"Zhang","year":"2020","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0969-2126(00)00020-4","article-title":"Structure of a soluble, glycosylated form of the human complement regulatory protein CD59","volume":"2","author":"Fletcher","year":"1994","journal-title":"Structure"},{"key":"ref_42","unstructured":"UniProt Consortium (2026). UniProt: P13987, CD59 Glycoprotein\u2014Homo Sapiens (Human), UniProt Consortium. Available online: https:\/\/www.uniprot.org\/uniprotkb\/P13987\/entry."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1016\/S0021-9258(18)42266-1","article-title":"The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the \u201cb\u201ddomain of C9","volume":"267","author":"Ninomiya","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","article-title":"Structural basis for membrane attack complex inhibition by CD59","volume":"14","author":"Couves","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"28","author":"Hadden","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/JBM.S543272","article-title":"Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders","volume":"16","author":"Tamdin","year":"2025","journal-title":"J. Blood Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.2020.185","article-title":"Gene Editing for the Treatment of Primary Immunodeficiency Diseases","volume":"32","author":"Rai","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., and Li, K. (2023). Advances in CRISPR\/Cas gene therapy for inborn errors of immunity. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1111777"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:08:04Z","timestamp":1791799684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":53,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197751"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197751","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}